Prabhudas Lilladher is bullish on Max Healthcare Institute has recommended buy rating on the stock with a target price of Rs 610 in its research report dated August 09, 2023. Read More Prabhudas Lilladher is bullish on Max Healthcare Institute… Read More »Buy Max Healthcare Institute; target of Rs 610: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Krishna Institute of Medical Sciences has recommended buy rating on the stock with a target price of Rs 2000 in its research report dated August 09, 2023. Read More Prabhudas Lilladher is bullish on Krishna… Read More »Buy Krishna Institute of Medical Sciences; target of Rs 2000: Prabhudas Lilladher
Prabhudas Lilladher is bullish on J.B. Chemicals and Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 3000 in its research report dated August 10, 2023. Read More Prabhudas Lilladher is bullish on J.B. Chemicals… Read More »Buy J.B. Chemicals and Pharmaceuticals Institute; target of Rs 3000: Prabhudas Lilladher
Lucrative periods like the August 15 holiday will help the India box office make up for the shortfall in the first half of 2023, said an analyst. Read More Lucrative periods like the August 15 holiday will help the India… Read More »Independence Day box office will touch Rs 100 crore from films like Jailer, Gadar 2, says analyst
Sales from the formulation business in India in Q1 was at Rs 1,064.3 crore over Rs 1,035.2 crore in the previous corresponding quarter, a growth of 2.8 per cent, the company said, adding, in North America, sales of finished dosage… Read More »Glenmark Pharma Q1 net profit falls 18% to Rs 173.13 crore
This subsidiary will focus on lending business operations, strengthening the company’s foothold in the lending segment. Abans Holdings is looking to become a dominant player in alternative investments. Read More This subsidiary will focus on lending business operations, strengthening the… Read More »Abans Holdings gets board#39;s nod to enter mutual funds space
Biocon Biologics, a fully integrated subsidiary of Biocon Ltd, focuses on making biosimilars, with key revenue-generating markets being the United States and Europe. Read More Biocon Biologics, a fully integrated subsidiary of Biocon Ltd, focuses on making biosimilars, with key… Read More »Biocon may list biosimilars business by 2025 first half – CEO
Net profit of the oil and gas explorer came in at Rs 17,383 crore in Q1, compared to Rs 8,581 crore in the year-ago period. Read More Net profit of the oil and gas explorer came in at Rs 17,383… Read More »ONGC Q1 results: Net profit soars 102% to Rs 17,383 crore
Biocon Biologics, a fully integrated subsidiary of Biocon Ltd, focuses on making biosimilars, with key revenue-generating markets being the United States and Europe. Read More Biocon Biologics, a fully integrated subsidiary of Biocon Ltd, focuses on making biosimilars, with key… Read More »Biocon may list biosimilars business by 2025 first half – CEO
Incorporated in 1986, Patanjali Foods (formerly known as Ruchi Soya Industries Ltd) is one of the leading firms in the edible oils segment and is aiming to become a major player in FMCG and FMHG as well. Read More Incorporated… Read More »Patanjali Foods Q1 profit down 64% to Rs 87.75 crore
English 
हिन्दी